M 3541

Drug Profile

M 3541

Alternative Names: M3541

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; Merck KGaA
  • Class Antineoplastics
  • Mechanism of Action Ataxia-telangiectasia mutated protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Sep 2017 Phase-I clinical trials in Solid tumours (Combination therapy) in USA (PO) (NCT03225105)
  • 27 Jul 2017 EMD Serono and Merck plans a phase I trial for Solid tumours(Combination therapy) in USA (PO) (NCT03225105)
  • 01 Jun 2017 Preclinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top